Table 1.
Overview of reported adverse events by treatment
| Treatment | Placebo* | Ponesimod (mg) | |||||
|---|---|---|---|---|---|---|---|
| 1 | 3 | 8 | 20* | 50 | 75 | ||
| Number of subjects | 12 | 6 | 6 | 6 | 6 | 6 | 6 |
| Number of subjects reporting at least one adverse event | 2 | 1 | 1 | 1 | 4 | 5 | 6 |
| Adverse event | |||||||
| Headache | 1 | 1 | – | – | 1 | 4 | 3 |
| Vertigo | – | – | – | 1 | 4 | 2 | 4 |
| Fatigue | 1 | – | – | – | – | 5 | 5 |
| Bradycardia | – | – | – | – | – | 2 | 5 |
| Dyspnoea | – | – | – | – | – | 2 | 5 |
| Nausea | 1 | – | – | – | 1 | 1 | – |
| Asthenia | – | – | – | – | – | – | 2 |
| Alanine aminotransferase increased | – | – | – | – | – | – | 1 |
| C-reactive protein increased | – | – | 1 | – | – | – | – |
| Dizziness | – | – | – | – | – | – | – |
| Euphoric mood | – | – | – | – | – | – | 1 |
| Forced expiratory volume decreased | – | – | – | – | – | – | 1 |
| Herpes simplex | – | – | – | – | – | – | 1 |
| Nasopharyngitis | – | – | 1 | – | – | – | – |
| Pyrexia | – | – | – | – | – | – | 1 |
| Vomiting | 1 | – | – | – | – | – | – |
*
Adverse events reported by subjects in the fed state are not shown.